Olga K Afanasiev
Overview
Explore the profile of Olga K Afanasiev including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
587
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Afanasiev O, Hung D, Yan S, Huang S, Cho B
J Am Acad Dermatol
. 2021 Apr;
85(1):206-209.
PMID: 33839210
No abstract available.
2.
Jing L, Ott M, Church C, Kulikauskas R, Ibrani D, Iyer J, et al.
Cancer Immunol Res
. 2020 Mar;
8(5):648-659.
PMID: 32179557
Merkel cell carcinoma (MCC) is often caused by persistent expression of Merkel cell polyomavirus (MCPyV) T-antigen (T-Ag). These non-self proteins comprise about 400 amino acids (AA). Clinical responses to immune...
3.
Afanasiev O, Tu J, Chu D, Swetter S
Pediatr Dermatol
. 2019 Apr;
36(4):448-454.
PMID: 30993772
Objectives: To characterize clinical differences among nonwhite/multiethnic vs white children, adolescents, and young adults with melanoma or atypical melanocytic neoplasms, including atypical Spitz tumors. Patients And Methods: A cohort of...
4.
Kim G, Afanasiev O, ODell C, Sharp C, Ko J
J Telemed Telecare
. 2018 Oct;
26(3):125-131.
PMID: 30301409
Introduction: Teledermatology services that function separately from patients’ primary electronic health record (EHR) can lead to fragmented care, poor provider communication, privacy concerns and billing challenges. This study addresses these...
5.
Afanasiev O, Zhang C, Ruhoy S
J Cutan Pathol
. 2017 Mar;
44(6):563-569.
PMID: 28332233
The increasingly successful and widespread use of Tumor Necrosis Factor inhibitors (TNFi) to treat autoimmune and inflammatory conditions has also been accompanied by adverse reactions, both systemic and cutaneous. Psoriasiform...
6.
Paulson K, Tegeder A, Willmes C, Iyer J, Afanasiev O, Schrama D, et al.
Cancer Immunol Res
. 2014 Aug;
2(11):1071-9.
PMID: 25116754
Merkel cell carcinoma (MCC) is an aggressive, polyomavirus-associated skin cancer. Robust cellular immune responses are associated with excellent outcomes in patients with MCC, but these responses are typically absent. We...
7.
Chapuis A, Afanasiev O, Iyer J, Paulson K, Parvathaneni U, Hwang J, et al.
Cancer Immunol Res
. 2014 Jan;
2(1):27-36.
PMID: 24432305
Merkel cell carcinoma (MCC) is an aggressive skin cancer that typically requires the persistent expression of Merkel cell polyomavirus (MCPyV) oncoproteins that can serve as ideal immunotherapeutic targets. Several immune...
8.
Afanasiev O, Yelistratova L, Miller N, Nagase K, Paulson K, Iyer J, et al.
Clin Cancer Res
. 2013 Aug;
19(19):5351-60.
PMID: 23922299
Purpose: The persistent expression of Merkel cell polyomavirus (MCPyV) oncoproteins in Merkel cell carcinoma (MCC) provides a unique opportunity to characterize immune evasion mechanisms in human cancer. We isolated MCPyV-specific...
9.
Afanasiev O, Nagase K, Simonson W, Vandeven N, Blom A, Koelle D, et al.
J Invest Dermatol
. 2013 Jan;
133(8):2065-73.
PMID: 23353989
Merkel cell carcinoma (MCC) is an aggressive, polyomavirus-linked skin cancer. Although CD8 lymphocyte infiltration into the tumor is strongly correlated with improved survival, these cells are absent or sparse in...
10.
Iyer J, Afanasiev O, McClurkan C, Paulson K, Nagase K, Jing L, et al.
Clin Cancer Res
. 2011 Sep;
17(21):6671-80.
PMID: 21908576
Purpose: Merkel cell polyomavirus (MCPyV) is prevalent in the general population, integrates into most Merkel cell carcinomas (MCC), and encodes oncoproteins required for MCC tumor growth. We sought to characterize...